Anixa Biosciences (NASDAQ:ANIX) Coverage Initiated at Maxim Group

Equities researchers at Maxim Group initiated coverage on shares of Anixa Biosciences (NASDAQ:ANIX - Get Free Report) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The firm set a "buy" rating and a $10.00 price target on the stock. Maxim Group's price target indicates a potential upside of 220.51% from the stock's current price.

A number of other equities research analysts also recently issued reports on the company. D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. HC Wainwright restated a "buy" rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, February 18th.

Anixa Biosciences Stock Down 1.3 %

Shares of NASDAQ ANIX traded down $0.04 during trading on Friday, reaching $3.12. 95,967 shares of the company traded hands, compared to its average volume of 97,332. The firm has a 50 day simple moving average of $2.89 and a 200-day simple moving average of $3.01. Anixa Biosciences has a 52-week low of $2.07 and a 52-week high of $4.20. The stock has a market capitalization of $100.45 million, a PE ratio of -8.00 and a beta of 0.86.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). As a group, research analysts predict that Anixa Biosciences will post -0.41 EPS for the current year.

Remove Ads

Insider Activity at Anixa Biosciences

In other news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the company's stock in a transaction that occurred on Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the acquisition, the director now owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Amit Kumar acquired 43,000 shares of the company's stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average cost of $2.23 per share, with a total value of $95,890.00. Following the purchase, the chief executive officer now owns 559,925 shares of the company's stock, valued at approximately $1,248,632.75. This trade represents a 8.32 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 75,289 shares of company stock worth $177,021. 25.30% of the stock is owned by company insiders.

Institutional Trading of Anixa Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Focus Partners Wealth bought a new stake in shares of Anixa Biosciences in the 4th quarter worth about $162,000. LPL Financial LLC raised its stake in shares of Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock valued at $100,000 after acquiring an additional 11,633 shares during the period. Westside Investment Management Inc. lifted its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company's stock worth $110,000 after acquiring an additional 21,100 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter worth about $67,000. Finally, Prosperity Wealth Management Inc. bought a new position in Anixa Biosciences during the 4th quarter valued at about $54,000. 29.13% of the stock is currently owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.